Exploring biochemical considerations for diffusive alpha radiation therapy (DaRT) models

Area of Science:

• Oncology
• Medical Physics
• Biochemistry

Background:

• Diffusing alpha-emitting Radiation Therapy (DaRT) is an emerging cancer treatment using localized 224-Radium seeds.
• DaRT's advantage lies in the diffusion of 224-Radium decay products for a more distributed dose.
• Current in silico models often overlook biochemical interactions within the tumor microenvironment (TME).

Purpose of the Study:

• To review the biochemical interactions of 212-Lead (212Pb) with the TME during DaRT treatments.
• To identify key binding molecules in the TME that influence 212Pb dosimetry.
• To guide the development of more accurate computational models for DaRT.

Main Methods:

• Literature review of 212Pb interactions and Pb-binding molecules in cancer tissue.
• Analysis of biochemical species known to bind lead and their prevalence in TME.
• Examination of molecular dynamics and variability of selected binding partners.

Main Results:

• Identified Glutathione (GSH), Metallothioneins (MTs), Calmodulin (CaM), and Human Serum Albumin (HSA) as key 212Pb binding partners in TME.
• These molecules exhibit known lead-binding capabilities and are present in cancer tissues.
• Variability in TME concentrations of these species affects DaRT dosimetry.

Conclusions:

• Accurate DaRT simulations require incorporating biochemical interactions within the TME.
• GSH, MTs, CaM, and HSA are critical molecular targets for modeling 212Pb behavior.
• This framework aids future research in optimizing DaRT efficacy through computational modeling.